Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients
NCT05071352Phase 3Completed
- Sponsor
- Cairo University
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nefopam in pain (2 arms), sponsored by Cairo University. Primary endpoint: Cumulative dose of fentanyl at 24 hours. Started Oct 2021; status: completed.
02
Drugs
nefopam
03
Conditions
pain
Beyond the preview
Go deeper on NCT05071352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071352.